Open Access
Open access
International Journal of Molecular Sciences, volume 22, issue 11, pages 5434

Existing Drugs Considered as Promising in COVID-19 Therapy

Edyta Janik Karpinska 1
Marcin Niemcewicz 1
Marcin Podogrocki 1
Joanna Saluk Bijak 2
M. Bijak 1
1
 
Biohazard Prevention Centre, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland
2
 
Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland
Publication typeJournal Article
Publication date2021-05-21
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor5.6
ISSN16616596, 14220067
Catalysis
Organic Chemistry
Inorganic Chemistry
Physical and Theoretical Chemistry
Computer Science Applications
Spectroscopy
Molecular Biology
General Medicine
Abstract

COVID-19 is a respiratory disease caused by newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease at first was identified in the city of Wuhan, China in December 2019. Being a human infectious disease, it causes high fever, cough, breathing problems. In some cases it can be fatal, especially in people with comorbidities like heart or kidney problems and diabetes. The current COVID-19 treatment is based on symptomatic therapy, so finding an appropriate drug against COVID-19 remains an immediate and crucial target for the global scientific community. Two main processes are thought to be responsible for the COVID-19 pathogenesis. In the early stages of infection, disease is determined mainly by virus replication. In the later stages of infection, by an excessive immune/inflammatory response, leading to tissue damage. Therefore, the main treatment options are antiviral and immunomodulatory/anti-inflammatory agents. Many clinical trials have been conducted concerning the use of various drugs in COVID-19 therapy, and many are still ongoing. The majority of trials examine drug reposition (repurposing), which seems to be a good and effective option. Many drugs have been repurposed in COVID-19 therapy including remdesivir, favipiravir, tocilizumab and baricitinib. The aim of this review is to highlight (based on existing and accessible clinical evidence on ongoing trials) the current and available promising drugs for COVID-19 and outline their characteristics.

Top-30

Citations by journals

1
2
3
4
International Journal of Molecular Sciences
4 publications, 15.38%
Vaccines
2 publications, 7.69%
Mathematics
1 publication, 3.85%
Biomedicines
1 publication, 3.85%
Frontiers in Immunology
1 publication, 3.85%
Frontiers in Molecular Biosciences
1 publication, 3.85%
Pharmaceutics
1 publication, 3.85%
Clinical Reviews in Allergy and Immunology
1 publication, 3.85%
Scientific data
1 publication, 3.85%
EClinicalMedicine
1 publication, 3.85%
Journal of Medical Virology
1 publication, 3.85%
BioEssays
1 publication, 3.85%
Environmental Science and Technology Letters
1 publication, 3.85%
Journal of Mathematics
1 publication, 3.85%
AIP Conference Proceedings
1 publication, 3.85%
Polycyclic Aromatic Compounds
1 publication, 3.85%
Revista Contemporânea
1 publication, 3.85%
ACS Omega
1 publication, 3.85%
Russian Chemical Reviews
1 publication, 3.85%
1
2
3
4

Citations by publishers

1
2
3
4
5
6
7
8
9
Multidisciplinary Digital Publishing Institute (MDPI)
9 publications, 34.62%
Frontiers Media S.A.
2 publications, 7.69%
Springer Nature
2 publications, 7.69%
Wiley
2 publications, 7.69%
American Chemical Society (ACS)
2 publications, 7.69%
Cold Spring Harbor Laboratory
2 publications, 7.69%
Elsevier
1 publication, 3.85%
Hindawi Limited
1 publication, 3.85%
American Institute of Physics (AIP)
1 publication, 3.85%
Taylor & Francis
1 publication, 3.85%
South Florida Publishing LLC
1 publication, 3.85%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.85%
1
2
3
4
5
6
7
8
9
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Janik Karpinska E. et al. Existing Drugs Considered as Promising in COVID-19 Therapy // International Journal of Molecular Sciences. 2021. Vol. 22. No. 11. p. 5434.
GOST all authors (up to 50) Copy
Janik Karpinska E., Niemcewicz M., Podogrocki M., Saluk Bijak J., Bijak M. Existing Drugs Considered as Promising in COVID-19 Therapy // International Journal of Molecular Sciences. 2021. Vol. 22. No. 11. p. 5434.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/ijms22115434
UR - https://doi.org/10.3390/ijms22115434
TI - Existing Drugs Considered as Promising in COVID-19 Therapy
T2 - International Journal of Molecular Sciences
AU - Podogrocki, Marcin
AU - Janik Karpinska, Edyta
AU - Niemcewicz, Marcin
AU - Saluk Bijak, Joanna
AU - Bijak, M.
PY - 2021
DA - 2021/05/21 00:00:00
PB - Multidisciplinary Digital Publishing Institute (MDPI)
SP - 5434
IS - 11
VL - 22
SN - 1661-6596
SN - 1422-0067
ER -
BibTex |
Cite this
BibTex Copy
@article{2021_Janik Karpinska,
author = {Marcin Podogrocki and Edyta Janik Karpinska and Marcin Niemcewicz and Joanna Saluk Bijak and M. Bijak},
title = {Existing Drugs Considered as Promising in COVID-19 Therapy},
journal = {International Journal of Molecular Sciences},
year = {2021},
volume = {22},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
month = {may},
url = {https://doi.org/10.3390/ijms22115434},
number = {11},
pages = {5434},
doi = {10.3390/ijms22115434}
}
MLA
Cite this
MLA Copy
Janik Karpinska, Edyta, et al. “Existing Drugs Considered as Promising in COVID-19 Therapy.” International Journal of Molecular Sciences, vol. 22, no. 11, May. 2021, p. 5434. https://doi.org/10.3390/ijms22115434.
Found error?